洲明科技(300232.SZ):約763.69萬股限售股12月20日解禁
格隆匯12月16日丨洲明科技(300232.SZ)公佈,此次解除限售股份的數量為約763.69萬股,佔截至2019年12月13日公司總股本的0.8277%;於解禁日實際可上市流通限售股份數量為約763.69萬股,佔截至2019年12月13日公司總股本的0.8277%。
公司於2019年12月2日收到非公開發行股票認購股東林洺鋒出具的書面承諾函,自願將其直接持有的洲明科技首發後限售股(2016年非公開發行股票認購股份)的限售期延長12個月,故林洺鋒認購的股份此次不申請解除限售。此次限售股份可上市流通日為2019年12月20日(星期五)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.